Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ATRA | US
0.54
7.65%
Healthcare
Biotechnology
30/06/2024
30/08/2024
7.60
7.13
7.67
7.13
Atara Biotherapeutics Inc. develops therapies for patients with solid tumors hematologic cancers and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel) a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks California.
View LessStrength based on increasing price with high volume
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
45.1%1 month
85.9%3 months
100.3%6 months
90.9%-
-
1.97
-0.81
0.77
-0.35
0.88
-
-162.12M
37.35M
37.35M
-
-62.41
-
2.89K
-2.01K
7.00
7.81
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.17
Range1M
3.90
Range3M
12.61
Rel. volume
1.33
Price X volume
597.04K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Elicio Therapeutics Inc. | ELTX | Biotechnology | 3.8 | 40.94M | -5.00% | 4.13 | -388.56% |
ProMIS Neurosciences Inc. | PMN | Biotechnology | 1.3662 | 40.83M | 5.09% | n/a | 0.00% |
OKYO Pharma Limited | OKYO | Biotechnology | 1.2 | 40.60M | -9.77% | n/a | -107.88% |
Aligos Therapeutics Inc | ALGS | Biotechnology | 12.68 | 40.53M | -3.65% | n/a | 14.63% |
Dyadic International Inc | DYAI | Biotechnology | 1.34 | 39.50M | -2.19% | n/a | 175.64% |
vTv Therapeutics Inc | VTVT | Biotechnology | 15.71 | 38.22M | -0.82% | n/a | 1.55% |
Equillium Inc | EQ | Biotechnology | 1.07 | 37.90M | -0.93% | n/a | 2.71% |
Xilio Therapeutics Inc. Common Stock | XLO | Biotechnology | 0.8579 | 37.71M | 6.76% | n/a | 25.98% |
Reviva Pharmaceuticals Holdings Inc. | RVPH | Biotechnology | 1.12 | 37.06M | 5.66% | n/a | 0.00% |
FibroGen Inc | FGEN | Biotechnology | 0.3656 | 36.71M | -1.48% | n/a | -70.49% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 3.68 | 39.85M | -1.12% | n/a | 54.96% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.34 | 28.51M | 13.04% | n/a | 16.03% |
ILAG | ILAG | Building Products & Equipment | 1.25 | 22.57M | 6.84% | n/a | 5.48% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 0.6131 | 18.67M | -4.20% | n/a | 204.46% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2495 | 3.93M | 5.94% | n/a | 0.00% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.391 | 3.72M | -6.28% | n/a | 19.98% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.45 | 3.70M | 13.28% | n/a | 9.62% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.47 | 2.11M | -7.84% | n/a | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.35 | 0.97 | Cheaper |
Ent. to Revenue | 0.88 | 3,681.29 | Cheaper |
PE Ratio | - | 39.83 | - |
Price to Book | 1.97 | 14.54 | Cheaper |
Dividend Yield | - | 2.19 | - |
Std. Deviation (3M) | 100.34 | 76.13 | Riskier |
Debt to Equity | -0.81 | -2.05 | Expensive |
Debt to Assets | 0.77 | 0.25 | Expensive |
Market Cap | 37.35M | 4.04B | Emerging |